Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-005026-20
    Sponsor's Protocol Code Number:mRNA-1345-P301
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-03-18
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-005026-20
    A.3Full title of the trial
    A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥ 60 Years of Age
    Estudio de fase 2/3, aleatorizado, con observador ciego y controlado con placebo para evaluar la seguridad y la eficacia de mRNA-1345, una vacuna de ARNm contra el virus respiratorio sincitial (VRS), en adultos a partir de 60 años de edad.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥ 60 Years of Age
    Estudio para evaluar la seguridad y la eficacia de mRNA-1345, una vacuna de ARNm contra el virus respiratorio sincitial (VRS), en adultos a partir de 60 años de edad.
    A.4.1Sponsor's protocol code numbermRNA-1345-P301
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorModernaTX, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportModernaTX, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationModernaTX, Inc.
    B.5.2Functional name of contact pointClinical Trials
    B.5.3 Address:
    B.5.3.1Street Address200 Technology Square
    B.5.3.2Town/ cityCambridge
    B.5.3.3Post codeMA 02139
    B.5.3.4CountryUnited States
    B.5.4Telephone number900834223
    B.5.6E-mailRegistroEspanolDeEstudiosClinicos@druginfo.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code mRNA-1345
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNUnknown
    D.3.9.1CAS number 2692611-88-2
    D.3.9.2Current sponsor codeCX-023398
    D.3.9.3Other descriptive nameRESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN VACCINE
    D.3.9.4EV Substance CodeSUB181711
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number0.60 to 1.0
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboIntramuscular use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Respiratory Syncytial Virus Infection
    Infección por el virus respiratorio sincitial
    E.1.1.1Medical condition in easily understood language
    RSV Infection
    Infección por VRS
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10061603
    E.1.2Term Respiratory syncytial virus infection
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    •To evaluate the safety and tolerability of the mRNA 1345 vaccine.
    •To demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV LRTD as compared with placebo within the period of 14 days postinjection up to 12 months postinjection.
    • Evaluar la seguridad y la tolerabilidad de la vacuna mRNA 1345.
    • Demostrar la eficacia de una dosis única de la vacuna mRNA 1345 para prevenir la aparición de un primer episodio de una enfermedad de las vías respiratorias bajas asociada al VRS (EVRB-VRS) en comparación con un placebo en el período comprendido entre 14 días y 12 meses después de la vacunación.
    E.2.2Secondary objectives of the trial
    Key Secondary Efficacy Objectives:

    • To evaluate the efficacy of a single dose of mRNA 1345 vaccine in the prevention of a first episode of RSV ARD as compared with placebo within the period of 14 days postinjection up to 12 months postinjection.
    • To evaluate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of hospitalizations associated with RSV ARD or RSV LRTD as compared with placebo within the period of 14 days postinjection up to 12 months postinjection.
    Objetivos secundarios fundamentales de la eficacia:
    • Evaluar la eficacia de una dosis única de la vacuna mRNA 1345 para prevenir la aparición de un primer episodio de una enfermedad respiratoria aguda asociada al VRS (ERA VRS) en comparación con un placebo en el período comprendido entre 14 días y 12 meses después de la vacunación.
    • Evaluar la eficacia de una dosis única de la vacuna mRNA-1345 para prevenir las hospitalizaciones por ERA VRS o EVRB VRS en comparación con un placebo en el período comprendido entre 14 días y 12 meses después de la vacunación.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Adults ≥ 60 years of age who are primarily responsible for self care and activities of daily living. Participants may have one or more chronic medical diagnoses (specifically CHF including heart failure with preserved ejection fraction and COPD), but should be medically stable as assessed by the following criteria:
    o Absence of changes in medical therapy within 1 month due to treatment failure or toxicity
    o Absence of medical events qualifying as SAEs within 1 month of the planned study injection on Day 1
    o Absence of known, current, and life-limiting diagnoses, which could continue for the duration of the primary efficacy period (12 months from study injection on Day 1) and which, in the opinion of the investigator, would make completion of the protocol unlikely.
    2. Body mass index from ≥ 18 kg/m2 to ≤ 35 kg/m2.
    3. Willing and able (on both a physical and cognitive basis) to give informed consent prior to study enrollment.
    4. Able to comply with study requirements.
    1. Adultos ≥60 años capaces de encargarse de los cuidados personales y de las actividades cotidianas. A los participantes se les pueden haber diagnosticado una o más enfermedades crónicas (concretamente ICC, incluida la insuficiencia cardíaca con fracción de eyección conservada, y EPOC), pero deben tener un estado clínico estable según los criterios siguientes:
    o Ausencia de cambios en el tratamiento médico en 1 mes por fracaso terapéutico o toxicidad.
    o Ausencia de acontecimientos médicos que cumplan los criterios de AAG en el mes anterior a la administración de la vacuna prevista del estudio el día 1.
    o Ausencia de diagnósticos conocidos, actuales e incapacitantes que podrían continuar durante el período de valoración principal de la eficacia (12 meses desde la administración de la vacuna del estudio el día 1) y que, en opinión del investigador, haría improbable la finalización del protocolo.
    2. Índice de masa corporal de ≥18 kg/m2 a ≤35 kg/m2.
    3. Voluntad y capacidad (tanto física como cognitiva) para otorgar el consentimiento informado antes de participar en el estudio.
    4. Capacidad para cumplir los requisitos del estudio.
    E.4Principal exclusion criteria
    1. Participation in another clinical research study where participant has received an investigational product (drug/biologic/device including any investigational RSV product) within 45 days before the planned date of the Day 1 study injection.
    2. History of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. Clinically unstable is defined as a diagnosis or condition requiring significant changes in management or medication within the 2 months prior to Screening and includes ongoing workup of an undiagnosed illness that could lead to a new diagnosis or condition.
    3. Reported history of congenital or acquired immunodeficiency, immunosuppressive condition, or immune-mediated disease.
    Note: Human immunodeficiency virus (HIV) positive participants with CD4 count ≥ 350 cells/mm3 and an undetectable HIV viral load within the past year (low level variations from 50-500 viral copies which do not lead to changes in antiretroviral therapy) as determined from participant’s medical records, are permitted.
    4. Dermatologic conditions that could affect local solicited AR assessments (eg, tattoos, psoriasis patches affecting skin over the deltoid areas).
    5. Reported history of anaphylaxis or severe hypersensitivity reaction after receipt of the mRNA-1345 vaccine or any components of the mRNA-1345 vaccine.
    6. Reported history of bleeding disorder that is considered a contraindication to IM injection or phlebotomy.
    7. History of a serious reaction to any prior vaccination, or Guillain-Barré syndrome within 6 weeks of any prior influenza immunization.
    8. Received or plans to receive any nonstudy vaccine (including authorized or approved vaccines for the prevention of coronavirus disease 2019 [COVID 19] regardless of type of vaccine) within 28 days before or after the Day 1 study injection. Nonstudy vaccination(s) should not be delayed.
    9. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study injection. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
    10. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study injection or during the study.
    11. Acute disease at the time of enrollment (defined as the presence of moderate or severe illness with or without fever, or an oral temperature ≥ 37.8°C on the planned day of vaccine administration).
    12. Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
    13. Known history of poorly controlled hypertension (per determination of the investigator), or systolic blood pressure > 160 mmHg at the Screening or baseline (Day 1) visit.
    14. Known history of hypotension, or systolic blood pressure < 85 mmHg at the Screening or baseline (Day 1) visit.
    15. Diastolic blood pressure > 90 mmHg at the Screening or baseline (Day 1) visit.
    16. Known uncontrolled disorder of coagulation.
    Note: Participants receiving aspirin, clopidogrel, prasugrel, dipyridamole, dabigatran, apixaban, rivaroxaban, or warfarin for cardiovascular prophylaxis or prophylaxis of thromboembolic disease or stroke in the setting of atrial fibrillation and under good control will NOT be excluded.
    17. History of myocarditis, pericarditis, or myopericarditis within 2 months prior to Screening. Participants who have not returned to baseline after their convalescent period will also be excluded.
    18. Donated ≥ 450 mL of blood products < 14 days prior to Screening.
    19. Member of study personnel or is an immediate family member or household member of study personnel.
    1. Participación en otro estudio de investigación clínica en el que el participante haya recibido un producto en investigación (fármaco, producto biológico o dispositivo, incluido cualquier producto experimental contra el VRS) en los 45 días previos a la fecha prevista de la administración de la vacuna del estudio el día 1.
    2. Antecedentes de un diagnóstico o afección que, en opinión del investigador, sea clínicamente inestable o pueda afectar a la seguridad del participante, a la evaluación de los criterios de valoración de la seguridad, a la evaluación de la respuesta inmunitaria o al cumplimiento de los procedimientos del estudio. Ser clínicamente inestable se define como un diagnóstico o afección que haya requerido cambios importantes en el tratamiento o la medicación en los 2 meses previos a la selección e incluye la realización de pruebas complementarias en curso de una enfermedad no diagnosticada que podría dar lugar a un nuevo diagnóstico o afección.
    3. Antecedentes notificados de inmunodeficiencia congénita o adquirida, enfermedades inmunodepresoras o enfermedades de origen inmunitario. Nota: Podrán participar personas infectadas por el virus de la inmunodeficiencia humana (VIH) con un número de CD4 ≥350 células/mm3 y una carga vírica del VIH indetectable en el último año (niveles bajos que oscilen entre 50 y 500 copias víricas y que no den lugar a modificaciones en el tratamiento antirretroviral) según lo determinado a partir de la historia clínica del participante.
    4. Alteraciones dermatológicas que podrían afectar a las evaluaciones de RA locales de notificación solicitada (p. ej., tatuajes o placas de psoriasis que afectan a la piel de la zona del deltoides).
    5. Antecedentes notificados de anafilaxia o de una fuerte reacción alérgica tras la recepción de la vacuna mRNA-1345 o cualquiera de sus componentes.
    6. Antecedentes notificados de trastornos hemorrágicos que se consideren una contraindicación para las inyecciones IM o la extracción de sangre.
    7. Antecedentes de reacciones graves a cualquier vacuna previa o presencia del síndrome de Guillain-Barré en las 6 semanas siguientes tras recibir la vacuna antigripal.
    8. Haber recibido o tener previsto recibir cualquier vacuna ajena al estudio (como las vacunas autorizadas o aprobadas para la prevención de la enfermedad por coronavirus de 2019 [COVID 19] con independencia del tipo de vacuna) en los 28 días anteriores o posteriores a la administración de la vacuna del estudio el día 1. No debería demorarse la inoculación de vacunas ajenas al estudio.
    9. Administración prolongada (definida como más de 14 días seguidos) de inmunodepresores u otros fármacos inmunomoduladores en los 6 meses previos a la administración de la vacuna del estudio. En el caso de los glucocorticoides, se considerará dosis inmunodepresora la dosis sistémica de ≥10 mg de prednisona al día o equivalente. Se permitirá el uso de glucocorticoides tópicos, inhalados y nasales.
    10. Administración de inmunoglobulinas o cualquier hemoderivado en los 3 meses previos a la administración de la vacuna del estudio o durante este.
    11. Enfermedad aguda en el momento de la inclusión (definida como la presencia de enfermedad moderada o grave con o sin fiebre, o una temperatura bucal ≥37,8 °C el día previsto de la administración de la vacuna).
    12. Cualquier problema de salud, psiquiátrico o enfermedad laboral, incluidos los antecedentes notificados de drogadicción o alcoholismo, que, en opinión del investigador, podrían suponer un riesgo adicional como consecuencia de la participación en el estudio o interferir en la interpretación de los resultados del estudio.
    13. Antecedentes conocidos de hipertensión mal controlada (según la determinación del investigador) o tensión arterial sistólica >160 mm Hg en la selección o en la visita basal (día 1).
    14. Antecedentes conocidos de hipotensión o tensión arterial sistólica <85 mm Hg en la selección o en la visita basal (día 1).
    15. Tensión arterial diastólica >90 mm Hg en la selección o en la visita basal (día 1).
    16. Presencia de trastornos de la coagulación no controlados. Nota: NO se excluirá a los participantes que reciban ácido acetilsalicílico, clopidogrel, prasugrel, dipiridamol, dabigatrán, apixabán, rivaroxabán o warfarina como profilaxis cardiovascular o profilaxis de una enfermedad tromboembólica o de un accidente cerebrovascular en personas con fibrilación auricular bien controlada.
    17. Antecedentes de miocarditis, pericarditis o miopericarditis en los 2 meses previos a la selección. También quedarán excluidos los participantes que no hayan vuelto a la situación basal después del período de convalecencia.
    18. Donación de ≥450 ml de hemoderivados <14 días antes de la selección.
    19. Miembros del personal del estudio o sus parientes cercanos o núcleo familiar.
    E.5 End points
    E.5.1Primary end point(s)
    Safety endpoints:
    • Numbers and percentages of participants with solicited local and systemic adverse reactions (ARs) up to 7 days postinjection.
    • Unsolicited adverse events (AEs) up to 28 days postinjection.
    • Medically attended adverse events (MAAEs), adverse events of special interest (AESIs), serious adverse events (SAEs), and AEs leading to withdrawal up to 24 months postinjection.

    Efficacy Endpoint:
    • Vaccine efficacy of mRNA-1345 to prevent a first episode of RSV-LRTD within the period of 14 days postinjection up to 12 months postinjection.
    Criterios de valoración de la seguridad:
    • Número y porcentaje de participantes con reacciones adversas (RA) locales y sistémicas declaradas en respuesta a preguntas hasta 7 días después de la vacunación.
    • Acontecimientos adversos (AA) declarados espontáneamente por los participantes hasta 28 días después de la vacunación.
    • Acontecimientos adversos con necesidad de atención médica (AAAM), acontecimientos adversos de especial interés (AAEI), acontecimientos adversos graves (AAG) y AA que motiven la retirada hasta 24 meses después de la vacunación.

    Criterio de valoración de la eficacia:
    • Eficacia vacunal de mRNA 1345 para prevenir la aparición de un primer episodio de EVRB VRS en el período comprendido entre 14 días y 12 meses después de la vacunación.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Screening
    D1 (Baseline)
    D8
    D15
    D29
    D60 then Monthly
    D181
    D365
    D546
    D730/EOS
    D730/EOS
    Selección
    Día 1 (visita basal)
    Día 8
    Día 15
    Día 29
    Día 60 y mensualmente a continuación
    Día 181
    Día 365
    Día 546
    Día 730/Fin de estudio
    E.5.2Secondary end point(s)
    • Vaccine efficacy of mRNA-1345 to prevent a first episode of RSV ARD within the period of 14 days postinjection up to 12 months postinjection.
    • Vaccine efficacy of mRNA 1345 to prevent hospitalizations associated with RSV ARD or RSV LRTD within the period of 14 days postinjection up to 12 months postinjection.
    •Vaccine efficacy of mRNA-1345 to prevent a first episode of RSV-LRTD within the period of 14 days postinjection up to 24 months postinjection.
    •Vaccine efficacy of mRNA-1345 to prevent a first episode of all-cause LRTD within the period of 14 days postinjection up to 12 months postinjection.
    •Vaccine efficacy of mRNA-1345 to prevent all-cause hospitalizations within the period of 14 days postinjection up to 12 months postinjection.
    • Eficacia vacunal de mRNA 1345 para prevenir la aparición de un primer episodio de ERA VRS en el período comprendido entre 14 días y 12 meses después de la vacunación.
    • Eficacia vacunal de mRNA 1345 para prevenir las hospitalizaciones por ERA VRS o EVRB VRS en el período comprendido entre 14 días y 12 meses después de la vacunación.
    • Eficacia vacunal de mRNA 1345 para prevenir la aparición de un primer episodio de EVRB VRS en el período comprendido entre 14 días y 24 meses después de la vacunación.
    • Eficacia vacunal de mRNA 1345 para prevenir la aparición de un primer episodio de EVRB por cualquier causa en el período comprendido entre 14 días y 12 meses después de la vacunación.
    • Eficacia vacunal de mRNA 1345 para prevenir las hospitalizaciones por cualquier causa en el período comprendido entre 14 días y 12 meses después de la vacunación.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Screening
    D1 (Baseline)
    D8
    D15
    D29
    D60 then Monthly
    D181
    D365
    D546
    D730/EOS
    Selección
    Día 1 (visita basal)
    Día 8
    Día 15
    Día 29
    Día 60 y mensualmente a continuación
    Día 181
    Día 365
    Día 546
    Día 730/Fin de estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    Immunogenicity
    Tolerabilidad
    Inmunogenicidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA53
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Brazil
    Canada
    Chile
    Colombia
    Costa Rica
    Japan
    Korea, Republic of
    Mexico
    New Zealand
    Panama
    Puerto Rico
    Singapore
    South Africa
    Taiwan
    United States
    Belgium
    Finland
    Germany
    Poland
    United Kingdom
    Netherlands
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Subject Last Visit
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 3360
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 30240
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients No
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state450
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 3365
    F.4.2.2In the whole clinical trial 33600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None.
    Nada.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-05-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-04-25
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Apr 29 08:01:39 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA